Inflammatory Bowel Disease Drugs Market To Reach $9.3bn In 2019, A New Study Predicts

12 September 2018
Pharma

A new report by visiongain forecasts the world market for inflammatory bowel disease medicines will reach $9.3 billion in 2019. That revenue prediction and others appear in Inflammatory Bowel Diseases (IBD) 2016-2026: Revenue Forecasts and R&D for Aminosalicylates, Antibiotics, Corticosteroids, Biologics and Immunomodulators Treating Disorders Including Crohn’s Disease and Ulcerative Colitis. Visiongain, a business information publisher and consultancy in London, UK, published that study in January 2016.

Visiongain predicts that the IBD pharmaceuticals market will grow in revenues owing to the increasing use of biological therapies (biologics), such as monoclonal antibodies (mAbs). Although biologics account for a small part of prescriptions at present, they dominate the market for revenue generation and held 68% of the global IBD market in 2014. From 2016 that worldwide market will be stimulated by rising disease incidence and non-invasive diagnosis, as well as technological advances in medicines. That industry’s R&D holds promise.

Sandra Wenas, a senior pharmaceutical industry analyst in visiongain, said: “The worldwide inflammatory bowel drug market will show moderate sales growth over the next four years from 2016. Patent expiries for Humira and Remicade during our forecast period will bring the market value significantly lower. New drugs entering the market are not expected to offset this loss.

“An increased use of biologics will be the main sales driver to 2026. As more doctors advocate the top-down therapy approach, and more studies justify the cost effectiveness of monoclonal antibodies for IBD, biological drugs’ revenues will expand and claim 57% of the IBD treatment market’s revenues by 2026. Aminosalicylates, however, will remain an important option for patients, especially those in poor countries, as the cost advantage of aminosalicylates will be more pronounced in those regions.”

Visiongain’s new analysis shows revenue forecasts to 2026 at overall world market, submarket, product and national level. First it forecasts five world-level submarkets:

• Biologics, including monoclonal antibodies (mAbs)
• Aminosalicylates
• Antibiotics
• Corticosteroids
• Immunomodulators.

That investigation next predicts the revenues of 17 leading IBD drugs to 2026, including Humira, Remicade, Asacol, Pentasa, Lialda, Tysabri, Cimzia, Entocort and recently approved treatments Uceris, Simponi and Entyvio.

Visiongain’s analysis includes trends and revenue predictions of 11 leading national markets to 2026:

• US
• Japan
• EU5:Germany, France, UK, Spain and Italy
• BRIC: Brazil, Russia, India and China.

The study also discusses research and development, including agents in these classes:

• Interleukin (IL) inhibitors
• Cell-adhesion molecule (CAM) inhibitors
• TNF-alpha inhibitors
• Stem cell therapies
• JAK inhibitors
• Toll-like receptor agonists.

That new report includes qualitative analyses and interviews with two authorities in that field. It also discusses leading companies: AbbVie, Janssen Biotech, Allergan and Shire Pharmaceuticals.

Inflammatory Bowel Diseases (IBD) 2016-2026 adds to visiongain’s range of analytical reports on industries and markets in healthcare. Those studies cover pharmaceuticals, biotechnologies, medical devices, diagnostics and contract services.

Recent News

“Global Asthma & COPD Therapies market set to grow to $46bn by 2024” says new Visiongain report

ecent studies and expert opinion suggest that the asthma and COPD market is more segregated than previously believed.

19 March 2019

Read

“Global Anaesthesia Drugs market set to grow to $11.8bn by 2024” says new Visiongain report

The intravenous route is the most commonly used route of administration owing to its high effectiveness during critical surgeries, its high adoption in hospitals, and availability of advanced intravenous drugs which cater the need of surgeons.

19 March 2019

Read

“The Global Pharma Contract Sales market will be driven by cost saving and the need for more flexibility” says new Visiongain report

With higher-cost therapies in development, combined with increasing burdens on healthcare budgets from ageing populations and rising disease incidence, market access is becoming more challenging in countries worldwide.

28 February 2019

Read

“Drug Delivery Technologies market set to grow to $355bn by 2024” says new Visiongain report

The potential use of drug delivery technologies in product lifecycle management and the enhancement of drug efficacy in many therapeutic sectors will act as drivers for growth of the market over the coming decade.

28 February 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1